VMAT lattice radiotherapy produced 65% median shrinkage in bulky hepatocellular carcinoma
Twelve VMAT lattice courses produced 65% median tumor shrinkage and no local progression during short follow-up in bulky hepatocellular carcinoma.
Twelve VMAT lattice courses produced 65% median tumor shrinkage and no local progression during short follow-up in bulky hepatocellular carcinoma.
DCAF4 activated NRF2-dependent antioxidant defence and protected hepatocellular carcinoma against iodine-125 brachytherapy in preclinical models.
PVC was detected in 37 of 72 HCC tumors and was associated with poorer response and progression-free survival after SBRT, immunotherapy, and bevacizumab.
After stereotactic body radiation therapy for hepatocellular carcinoma, magnetic resonance response evolved over months, making early enhancement alone unreliable.
Respiratory gating more than halved cranio-caudal motion, while motion-related target-dose deviations largely diminished after accumulation across more than three fractions.